IFNG and primary cutaneous T-cell non-Hodgkin lymphoma: Indeed, administration of Toll-like receptor (TLR) agonists boosting cellular immunity has shown clinical efficacy, and treatment with IL-12 and IFNγ can induce regression of CTCL lesions which is associated with increased numbers of CD8 T cells in the resolving skin (Rook et al., 1999, 2001, 2015; Suchin et al., 2002; Dummer et al., 2004; Duvic et al., 2006; Wysocka et al., 2007; Kim et al., 2010; Accart et al., 2013).